

**Anti-IL-6 / IFN $\beta$ 2 Reference Antibody (elsilimomab)  
Recombinant Antibody  
Catalog # APR10266**

**Specification**

---

**Anti-IL-6 / IFN $\beta$ 2 Reference Antibody (elsilimomab) - Product Information**

|                   |                        |
|-------------------|------------------------|
| Application       | FC, E, FTA             |
| Primary Accession | <a href="#">P05231</a> |
| Reactivity        | Human                  |
| Clonality         | Monoclonal             |
| Isotype           | IgG1                   |
| Calculated MW     | 145 KDa                |

**Anti-IL-6 / IFN $\beta$ 2 Reference Antibody (elsilimomab) - Additional Information**

**Target/Specificity**

IL-6 / IFN $\beta$ 2

**Endotoxin**

< 0.001EU/  $\mu$ g,determined by LAL method.

**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Anti-IL-6 / IFN $\beta$ 2 Reference Antibody (elsilimomab) - Protein Information**

**Name** IL6 ([HGNC:6018](#))

**Synonyms** IFNB2

**Function**

Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans- signaling'. Alternatively, 'cluster signaling' occurs when membrane- bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).

**Cellular Location**

Secreted.


**Tissue Location**

Produced by skeletal muscle.


**Anti-IL-6 / IFN $\beta$ 2 Reference Antibody (elsilimomab) - Protocols**

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Anti-IL-6 / IFN $\beta$ 2 Reference Antibody (elsilimomab) - Images**

Anti-IL-6 / IFN $\beta$ 2 Reference Antibody (elsilimomab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-6 / IFN $\beta$ 2 Reference Antibody (elsilimomab) is more than 98.96% ,determined by SEC-HPLC.



Immobilized human IL-6 His at 2 µg/mL can bind Anti-IL-6 / IFN $\beta$ 2 Reference Antibody (elsilimomab)  $\square$ EC50=0.0162 µg/mL